Rifampicin-Loaded ‘Flower-Like’ Polymeric Micelles for Enhanced Oral Bioavailability in An Extemporaneous Liquid Fixed-Dose Combination with Isoniazid

• Kaufmann SH , McMichaelAJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med.11, S33–S44 (2005).
   PubMed Web of Science ®Google Scholar
• Frieden TR , SterlingTR, MunsiffSS, WattCJ, DyeC. Tuberculosis. Lancet362, 887–899 (2003).
   PubMed Web of Science ®Google Scholar
• Sharma S , SharmaPK, KumarN, DudheR. A review on various heterocyclic moieties and their antitubercular activity. Biomed. Pharmacother.65, 244–251 (2011).
   PubMed Web of Science ®Google Scholar
• Bertel Squire S , ThomsonS. Tuberculosis and poverty. In: Tuberculosis – A Comprehensive Clinical Reference. Schaaf SH, Zumla AL, Grange JM et al. (Eds). Saunders Elsevier, London, UK (2009).
   Google Scholar
• WHO declares tuberculosis a global emergency. Soc. Prevent. Med.38, 251–252 (1993).
   Google Scholar
• Rivers EC , ManceraRL. New antituberculosis drugs in clinical trials with novel mechanism of action. Drug Discov. Today13, 1090–1098 (2008).
   PubMed Web of Science ®Google Scholar
• Matteelli A , CarvalhoA, DooleyKE, KritskiA. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol.5, 849–858 (2010).
   PubMed Web of Science ®Google Scholar
• Cole ST , BroschR, ParkhillJet al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537–544 (1998).
   PubMed Web of Science ®Google Scholar
• Singh S , MariappanTT, ShardaN, KumarS, ChakrabartiAK. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun.6, 405–410 (2000).
   Google Scholar
• Shishoo CJ , ShahSA, RathodIS, SavaleSS, KotechaJS, ShahPB. Stability of rifampicin in dissolution medium in presence of isoniazid. Int. J. Pharm.190, 109–123 (1999).
   PubMed Web of Science ®Google Scholar
• Sankar R , ShardaN, SinghS. Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1–3. Drug Dev. Ind. Pharm.29, 733–738 (2003).
   PubMed Web of Science ®Google Scholar
• Shishoo CJ , ShahSA, RathodIS, SavaleSS. Impaired bioavailability of rifampicin from fixed dose combination (FDC) formulations with isoniazid. Indian J. Pharm. Sci.63, 443–449 (2001).
   Google Scholar
• Singh S , MariappanTT, SankarR, SardaN, SinghB. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combinations (FDC) products, and the likely solutions to the problem. Int. J. Pharm.228, 5–17 (2001).
   PubMedGoogle Scholar
• Blomberg B , SpinaciS, FourieB, LaingR. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. World Health Organ.79, 61–68 (2001).
   PubMed Web of Science ®Google Scholar
• Swaminathan S , RekhaB. Pediatric tuberculosis: global overview and challenges. Clin. Infect. Dis.50, S184–S194 (2010).
   PubMed Web of Science ®Google Scholar
• Trouiller P , OlliaroP, TorreeleE, OrbinskiJ, LaingR, FordN. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet359, 2188–2194 (2002).
   PubMed Web of Science ®Google Scholar
• Sosnik A , SeremetaKP, ImperialeJC, ChiappettaDA. Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases (PRDs). Expert Opin. Drug Deliv.9, 303–323 (2012).
   PubMed Web of Science ®Google Scholar
• Sosnik A , CarcabosoAM, GlisoniRJ, MorettonMA, ChiappettaDA. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Del. Rev.62, 547–559 (2010).
   PubMed Web of Science ®Google Scholar
• Choonara YE , PillayV, NdesendoVMet al. Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. Colloids Surf. B Biointerfaces 87, 243–254 (2011).
   PubMed Web of Science ®Google Scholar
• Sosnik A , CarcabosoA, ChiappettaDA. Polymeric nanocarriers: new endeavors for the optimization of the technological aspects of drugs. Recent Pat. Biomed. Eng.1, 43–59 (2008).
   Google Scholar
• Chiappetta DA , SosnikA. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm.66, 303–317 (2007).
   PubMed Web of Science ®Google Scholar
• Chiappetta DA , HochtC, TairaC, SosnikA. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailaibility. Nanomedicine (Lond.)5, 11–23 (2010).
   PubMed Web of Science ®Google Scholar
• Chiappetta DA , HochtC, TairaC, SosnikA. Oral pharmacokinetics of efavirenz-loaded polymeric micelles. Biomaterials32, 2379–2387 (2011).
   PubMed Web of Science ®Google Scholar
• Peroni RN , Di Gennaro SS, Hocht C et al. Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. Biochem. Pharmacol.82, 1227–1233 (2011).
   PubMed Web of Science ®Google Scholar
• Chiappetta DA , HochtC, OpezzoJA, SosnikA. Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV. Nanomedicine (Lond.)8, 223–237 (2013).
   PubMed Web of Science ®Google Scholar
• Ribeiro A , SosnikA, ChiappettaDA, VeigaF, ConcheiroA, Alvarez-LorenzoC. Single and mixed poloxamine micelles as suitable nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy. J. R. Soc. Interface9, 2059–2069 (2012).
   PubMed Web of Science ®Google Scholar
• Moretton MA , GlisoniRJ, ChiappettaDA, SosnikA. Molecular implications in the nanoencapsulation of the antituberculosis drug rifampicin within flower-like polymeric micelles. Colloids Surf. B Biointerfaces79, 467–479 (2010).
   PubMed Web of Science ®Google Scholar
• Moretton MA , ChiappettaDA, SosnikA. Cryoprotection–lyophilization and physical stabilization of rifampicin loaded flower-like polymeric micelles. J. R. Soc. Interface9, 487–502 (2012).
   PubMed Web of Science ®Google Scholar
• Gotelli G , BonelliP, AbrahamG, SosnikA. Fast and efficient synthesis of high molecular weight poly(ε-caprolactone) diols by microwave-assisted polymer synthesis (MAPS). J. Appl. Polym. Sci.121, 1321–1329 (2011).
   Web of Science ®Google Scholar
• Sosnik A , GotelliG, AbrahamGA. Microwave-assisted polymer synthesis (MAPS) as a tool in biomaterials science: how new and how powerful. Prog. Polym. Sci.36, 1050–1078 (2011).
   Web of Science ®Google Scholar
• Sreenivasa Rao B , Ramana Murthy KV. Studies on rifampicin release from ethylcellulose coated nonpareil beads. Int. J. Pharm.231, 97–106 (2002).
   PubMedGoogle Scholar
• Ritger PL , PeppasNA. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Release5, 23–36 (1987).
   Google Scholar
• Ritger PL , PeppasNA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release5, 37–42 (1987).
   Google Scholar
• Hu Y , DingY, LiY, JiangX, YangC, YangY. Physical stability and lyophilization of poly(caprolactone)-b-poly(ethyleneglycol)-b-poly(caprolactone) micelles. J. Nanosci. Nanotech.6, 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Chiappetta DA , HochtC, SosnikA. Highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Curr. HIV Res.8, 223–231 (2010).
   PubMed Web of Science ®Google Scholar
• Moretton MA , GlisoniRJ, ChiappettaDA, SosnikA. Synthesis and characterization of amphiphilic poly(ε-caprolactone)-poly(ethylene glycol) block copolymers. Optimization of the solubility and stability of rifampicin by means of encapsulation into polymeric micelles. Presented at: BIOOMAT 2009, I Workshop on Artificial Organs, Biomaterials and Tissue Engineering. Rosario, Argentina, 25–27 August 2009.
   Google Scholar
• Agrawal SK , Sanabria-DeLongN, CoburnJM, TewGN, BhatiaSR. Novel drug release profiles from micellar solutions of PLA–PEO–PLA triblock copolymers. J. Control. Release112, 64–71 (2006).
   PubMed Web of Science ®Google Scholar
• Bastakoti BP , GuragainS, YokoyamaY, Yusa S-I, Nakashima K. Incorporation and release behavior of amitriptylene in core–shell–corona type triblock copolymer micelles. Colloids Surf. B Biointerfaces88, 734–740 (2011).
   PubMed Web of Science ®Google Scholar
• Lin WJ , JuangLW, LinCC. Stability and release performance of a series of pegylated copolymeric micelles. Pharm. Res.20, 668–673 (2003).
   PubMed Web of Science ®Google Scholar
• Costa P , Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci.13, 123–133 (2001).
   PubMed Web of Science ®Google Scholar
• Wang Q , ZhangJ, WangA. Preparation and characterization of a novel pH-sensitive chitosan-g-poly (acrylic acid)/attapulgite/sodium alginate composite hydrogel bead for controlled release of diclofenac sodium. Carbohyd. Polym.78, 731–737 (2009).
   Web of Science ®Google Scholar
• Forrest ML , Won C-Y, Malick WA, Kwon GS. In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(-caprolactone) micelles. J. Control. Release110, 370–377 (2006).
   PubMed Web of Science ®Google Scholar
• Brewster ME , LoftssonT. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev.59, 645–666 (2007).
   PubMed Web of Science ®Google Scholar
• Tewes F , BrillaultJ, CouetW, Olivier J-C. Formulation of rifampicin–cyclodextrin complexes for lung nebulisation. J. Control. Release129, 93–99 (2008).
   PubMed Web of Science ®Google Scholar
• McConnell EL , BasitAW, MurdanS. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in vivo experiments. J. Pharm. Pharmacol.60, 63–70 (2004).
   Google Scholar
• Armijo JA . Absorción, distribución y eliminación de fármacos. In: Farmacología Humana (3rd Edition). Florez J, Armijo JA, Mediavilla A (Eds). Masson, Barcelona, Spain (1997).
   Google Scholar
• Loftsson T , BrewsterME. Cyclodextrins as functional excipients: methods to enhance complexation efficiency. J. Pharm. Sci.101, 3019–3032 (2012).
   PubMed Web of Science ®Google Scholar
• Loftsson T , BrewsterME. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J. Pharm. Pharmacol.63, 1119–1135 (2011).
   PubMed Web of Science ®Google Scholar
• Jansook P , LoftssonT. CDs as solubilizers: effects of excipients and competing drugs. Int. J. Pharm.379, 32–40 (2009).
   PubMedGoogle Scholar
• Jayaram R , GaonkarS, KaurPet al. Pharmacokinetics–pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47, 2118–2124 (2003).
   PubMed Web of Science ®Google Scholar

Websites

• WHO. Global Tuberculosis Report. www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf (Accessed January 2013)
   Google Scholar
• WHO. Treatment of tuberculosis: guidelines. http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf (Accessed January 2013)
   Google Scholar
• WHO. The top ten causes of death. www.who.int/mediacentre/factsheets/fs310/en/index.html (Accessed August 2012)
   Google Scholar
• WHO. Dosing instructions for the use of currently available fixed-dose combination TB medicines for children.www.who.int/tb/challenges/interim_paediatric_fdc_dosing_instructions_sept09.pdf (Accessed July 2013)
   Google Scholar
• WHO. WHO list of prequalified medicinal products.http://apps.who.int/prequal/query/ProductRegistry.aspx?list=tb (Accessed March 2013)
   Google Scholar